Europe PMC
open access
CC BY 4.0
Variation in uptake and dose reduction of CDK4/6 inhibitors for the treatment of breast cancer in England, 2019–2024: a descriptive observational study using OpenPrescribing Hospitals
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer#904023
- Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer#882787
- Clinical significance on switching CDK4/6 inhibitors among 13,284 patients with metastatic breast cancer#292640
- Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors#833298
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer#850480
Record · ID 475658
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive